Opinion|Videos|May 13, 2024

Treatment Decision-Making in Relapsed/Refractory Multiple Myeloma

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Samer A. Al'Hadidi, MD

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Samer Al'Hadidi, MD, to discuss treatment decision-making strategies for patients with relapsed/refractory multiple myeloma.

Episodes in this series

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 1 Monitoring Patients with Relapsed/Refractory Multiple Myeloma

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 2 The Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 3 Adverse Effect Management for CAR T-Cell Therapy and Bispecifics in R/R MM

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 4 Treatment Decision-Making in Relapsed/Refractory Multiple Myeloma

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 5 Advice for Community Oncologists Treating R/R Multiple Myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

October 29th, 2026

Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

$FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma$

October 27th, 2026

FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma

Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

October 27th, 2026

Elranatamab Improves PFS vs Standard Regimens in R/R Multiple Myeloma

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

October 24th, 2026

Belantamab Mafodotin Combo Yields High MRD Negativity in NDMM

In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

Trending on CancerNetwork

Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer

Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer

Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma

Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma

Which New Service Lines Should a Radiation Oncology Department Launch?